Fosinoprilat (BioDeep_00000015562)
代谢物信息卡片
化学式: C23H34NO5P (435.2174484000001)
中文名称: 福辛普利特-d7
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CCC(CC1)C2CC(N(C2)C(=O)CP(=O)(CCCCC3=CC=CC=C3)O)C(=O)O
InChI: InChI=1S/C23H34NO5P/c25-22(17-30(28,29)14-8-7-11-18-9-3-1-4-10-18)24-16-20(15-21(24)23(26)27)19-12-5-2-6-13-19/h1,3-4,9-10,19-21H,2,5-8,11-17H2,(H,26,27)(H,28,29)/t20-,21+/m1/s1
描述信息
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
同义名列表
1 个代谢物同义名
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:116962
- KEGG: C21542
- KEGGdrug: D03772
- PubChem: 62956
- DrugBank: DB14207
- ChEMBL: CHEMBL581
- CAS: 95399-71-6
- PubChem: 336445180
- PDB-CCD: KS8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
2 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(2)
- Fosinopril Action Pathway:
Fosinopril ⟶ Fosinoprilat - Fosinopril Metabolism Pathway:
Fosinopril ⟶ Fosinoprilat
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Swati D Bhende, Murali Balaram Varanasi, Konde Abbulu. A sensitive and efficient LC-MS/MS method for the bioanalysis of fosinopril diacid from human plasma and its application for a bioequivalence study in humans.
Biomedical chromatography : BMC.
2021 May; 35(5):e5047. doi:
10.1002/bmc.5047. [PMID: 33352616] - Kewen Xue, Gao Li, Xiao Sun, Yang Hu, Lei Hu, Jiangeng Huang, Luqin Si. Simultaneous quantification of fosinopril and its active metabolite fosinoprilat in rat plasma by UFLC-MS/MS: Application of formic acid in the stabilization of an ester-containing drug.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2015 May; 990(?):141-9. doi:
10.1016/j.jchromb.2015.03.028. [PMID: 25875586] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - B Jancic, D Ivanovic, M Medenica, A Malenovic, N Dimkovic. Development of liquid chromatographic method for fosinoprilat determination in human plasma using microemulsion as eluent.
Journal of chromatography. A.
2005 Sep; 1088(1-2):187-92. doi:
10.1016/j.chroma.2005.05.038. [PMID: 16130750] - H H Chen, J G Lainchbury, Y Matsuda, G J Harty, J C Burnett . Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure.
Hypertension (Dallas, Tex. : 1979).
2001 Aug; 38(2):187-91. doi:
10.1161/01.hyp.38.2.187. [PMID: 11509474] - M Jemal, D E Mulvana. Liquid chromatographic-electrospray tandem mass spectrometric method for the simultaneous quantitation of the prodrug fosinopril and the active drug fosinoprilat in human serum.
Journal of chromatography. B, Biomedical sciences and applications.
2000 Mar; 739(2):255-71. doi:
10.1016/s0378-4347(99)00551-4. [PMID: 10755370] - R Greenbaum, P Zucchelli, A Caspi, H Nouriel, R Paz, S Sclarovsky, P O'Grady, K F Yee, W C Liao, B Mangold. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency.
British journal of clinical pharmacology.
2000 Jan; 49(1):23-31. doi:
10.1046/j.1365-2125.2000.00103.x. [PMID: 10606834] - M Jemal, M Huang, Y Mao, D Whigan, A Schuster. Liquid chromatography/electrospray tandem mass spectrometry method for the quantitation of fosinoprilat in human serum using automated 96-well solid-phase extraction for sample preparation.
Rapid communications in mass spectrometry : RCM.
2000; 14(12):1023-8. doi:
10.1002/1097-0231(20000630)14:12<1023::aid-rcm983>3.0.co;2-k. [PMID: 10861982] - O Y Hu, P Y Ding, C S Huang, G M Hwang, K M Chu. Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration.
Journal of clinical pharmacology.
1997 Sep; 37(9):834-40. doi:
10.1002/j.1552-4604.1997.tb05632.x. [PMID: 9549638] - J B Kostis, W T Garland, C Delaney, J Norton, W C Liao. Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure.
Clinical pharmacology and therapeutics.
1995 Dec; 58(6):660-5. doi:
10.1016/0009-9236(95)90022-5. [PMID: 8529331] - N F Ford, K C Lasseter, D R Van Harken, J L Hammett, R Raymond, J Manning. Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment.
Journal of clinical pharmacology.
1995 Feb; 35(2):145-50. doi:
10.1002/j.1552-4604.1995.tb05003.x. [PMID: 7751424] - T W Gehr, D A Sica, D M Grasela, K L Duchin. The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients.
European journal of clinical pharmacology.
1993; 45(5):431-6. doi:
10.1007/bf00315514. [PMID: 8112372] - K L Duchin, A P Waclawski, J I Tu, J Manning, M Frantz, D A Willard. Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.
Journal of clinical pharmacology.
1991 Jan; 31(1):58-64. doi:
10.1002/j.1552-4604.1991.tb01887.x. [PMID: 1646240] - J I Tu, J Brennan, B Stouffer, W C Eckelman. A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum.
Therapeutic drug monitoring.
1990 Jul; 12(4):404-10. doi:
10.1097/00007691-199007000-00018. [PMID: 2144379] - R A Morrison, S M Singhvi, A E Peterson, D A Pocetti, B H Migdalof. Relative contribution of the gut, liver, and lung to the first-pass hydrolysis (bioactivation) of orally administered 14C-fosinopril sodium in dogs. In vivo and in vitro studies.
Drug metabolism and disposition: the biological fate of chemicals.
1990 Mar; 18(2):253-7. doi:
NULL. [PMID: 1971582] - J M DeForrest, T L Waldron, C Harvey, B Scalese, B Rubin, J R Powell, E W Petrillo, D W Cushman. Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology.
Journal of cardiovascular pharmacology.
1989 Nov; 14(5):730-6. doi:
10.1097/00005344-198911000-00009. [PMID: 2481187] - M Jemal, E Ivashkiv, M Ribick, A I Cohen. Determination of SQ 27,519, the active phosphinic acid-carboxylic acid of the prodrug SQ 28,555, in human serum by capillary gas chromatography with nitrogen-phosphorus detection after a two-step derivatization.
Journal of chromatography.
1985 Dec; 345(2):299-307. doi:
10.1016/0378-4347(85)80167-5. [PMID: 2935551] - B N Swanson, K L Stauber, W C Alpaugh, S H Weinstein. Radioenzymatic assay of angiotensin-converting enzyme inhibitors in plasma and urine.
Analytical biochemistry.
1985 Aug; 148(2):401-7. doi:
10.1016/0003-2697(85)90245-3. [PMID: 2998222]